REGULUS THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.42 USD | +6.61% |
|
+13.62% | +89.06% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18.63 | 90.32 | 45.98 | 23.07 | 25.89 | 158.4 | - | - |
| Enterprise Value (EV) 1 | -0.8649 | 63.88 | 45.98 | -1.157 | 6.216 | 64.23 | 107.6 | 62.63 |
| P/E ratio | -0.82 x | -3 x | -0.98 x | -0.74 x | -0.81 x | -4.77 x | -3.97 x | -3.75 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.73 x | 9.03 x | - | - | - | - | - | - |
| EV / Revenue | -0.13 x | 6.38 x | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | -0.2 x | -1.66 x | -2.12 x | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,093 | 6,690 | 14,597 | 16,840 | 20,223 | 65,465 | - | - |
| Reference price 2 | 8.900 | 13.50 | 3.150 | 1.370 | 1.280 | 2.420 | 2.420 | 2.420 |
| Announcement Date | 3/12/20 | 3/9/21 | 3/10/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.832 | 10.01 | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | -30.88 | -38.7 | -50.7 | - |
| EBIT 1 | -16.83 | -14.16 | -27.82 | -28.24 | -31.11 | -34.9 | -44.95 | -45.9 |
| Operating Margin | -246.4% | -141.47% | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.59 | -15.73 | -27.81 | -28.32 | -30.04 | -34.39 | -44.95 | -45.9 |
| Net income 1 | -18.59 | -15.73 | -27.81 | -28.32 | -30.04 | -33.69 | -46.6 | -54.25 |
| Net margin | -272.13% | -157.21% | - | - | - | - | - | - |
| EPS 2 | -10.80 | -4.500 | -3.200 | -1.860 | -1.580 | -0.5075 | -0.6100 | -0.6450 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/9/21 | 3/10/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -8.419 | -6.96 | -6.569 | -7.175 | -7.563 | -6.932 | -7.369 | -7.315 | -8.125 | -8.3 | -8.7 | -8.7 | -9.55 | -9.55 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.628 | -7.133 | -6.718 | -7.258 | -7.551 | -6.795 | -7.139 | -7.012 | -7.824 | -8.061 | -8.558 | -8.46 | -9.325 | -9.385 | - |
| Net income 1 | -8.628 | -7.133 | -6.719 | -7.258 | -7.551 | -6.795 | -7.139 | -7.013 | -7.824 | -8.061 | -8.072 | -8.107 | -8.917 | -9.223 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.000 | -0.7000 | -0.5000 | -0.5000 | -0.5000 | -0.4000 | -0.4200 | -0.3700 | -0.4000 | -0.4000 | -0.2225 | -0.1125 | -0.1175 | -0.1200 | -0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/10/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/8/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 19.5 | 26.4 | - | 24.2 | 19.7 | 94.2 | 50.8 | 95.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.36 | - | 0.7 | 0.7 | 0.8 |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/9/21 | 3/10/22 | 3/23/23 | 3/21/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.42
USD
Average target price
7.25
USD
Spread / Average Target
+199.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +89.06% | 158M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RGLS Stock
- Financials Regulus Therapeutics Inc.
